Table 1.
Samples used in this study.
| Sample | Type | Sequencer | Date | Days | Passage | Acc. No. |
|---|---|---|---|---|---|---|
| VVAG | Vaccine | MiSeq | 2009* | — | — | KF558383 |
| VV10 | Vaccine | MiSeq | 2010 | — | — | KF558384 |
| VV12 | Vaccine | MiSeq | 2012 | — | — | KF558385 |
| B86 | Vaccine | HiSeq | 1986* | — | — | KF853225 |
| A171B | Varicella | GAiix | 1988* | 14 | High | KF853226 |
| A182B | Varicella | GAiix | 1988* | 16 | High | KF558381 |
| A185B | Varicella | GAiix | 1988* | 21 | High | KF558382 |
| O27 | Varicella | GAiix | 1999* | 16 | None | KF558376 |
| VR2 | Varicella | MiSeq | 2007 | 17 | None | KF558372 |
| VR1 | Varicella | MiSeq | 2007 | 14 | None | KF558373 |
| R43 | Varicella | MiSeq | 2000* | 23 | None | KF853229 |
| VR5 | Varicella | MiSeq | 2008 | 16 | None | KF853233 |
| R3 | Zoster | GAiix | 1999* | 244 | Low | KF853228 |
| R52 | Zoster | GAiix | 1999* | 490 | Low | KF853230 |
| T17 | Zoster | GAiix | 2000* | 310 | Low | KF558378 |
| T25 | Zoster | GAiix | 2000* | 547 | Low | KF558379 |
| v76 | Zoster | GAiix | 1982* | 630 | Low | KF558380 |
| K11 | Zoster | MiSeq | 1997* | 75 | None | KF558391 |
| L53 | Zoster | MiSeq | 1997* | 131 | None | KF558389 |
| T61 | Zoster | GAiix | 2001* | 91 | None | KF558377 |
| ZR1 | Zoster | MiSeq | 2006 | 330 | None | KF558371 |
| Q27 | Zoster | MiSeq | 1998* | 541 | Low | KF853227 |
| ZR2 | Zoster | MiSeq | 2006 | 150 | None | KF853231 |
| ZR3 | Zoster | MiSeq | 2007 | 577 | None | KF853232 |
| ZR4 | Zoster | MiSeq | 2010 | 517 | None | KF853234 |
| ZR5 | Zoster | MiSeq | 2013 | 120 | None | KF853235 |
Note.—Type, either vaccine batch, patient samples from a vaccine varicella rash or vaccine zoster rash; Date, year of vaccine batch production or year of vaccination; Days, time interval between vaccination and rash development; Passage, rates of lab passaging prior to sequencing; Acc. No., GenBank accession numbers of consensus sequence.